Journal article

Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Abstract:: The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that would achieve similar effects to those of the biological agents. However, the effectiveness and safety of the biological agents has raised a very large hurdle that will need to be overcome if the potential cost benefit of such an inhibitor is to be realised.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Foxwell, B., Andreakos, E., Brennan, F., Feldmann, M., Smith, C., & Conron, M. (2003). Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Annals of the Rheumatic Diseases, 62 Suppl 2(SUPPL. 2), ii90–ii93.

MLA Style

Foxwell, B, et al. “Prospects for the Development of Small Molecular Weight Compounds to Replace Anti-Tumour Necrosis Factor Biological Agents.” Annals of the Rheumatic Diseases, 62 Suppl 2, no. SUPPL. 2, 2003, pp. ii90–ii93.

Chicago Style

Foxwell, B, E Andreakos, F Brennan, M Feldmann, C Smith, and M Conron. 2003. “Prospects for the Development of Small Molecular Weight Compounds to Replace Anti-Tumour Necrosis Factor Biological Agents.” Annals of the Rheumatic Diseases 62 Suppl 2 (SUPPL. 2): ii90–ii93.
Print

Access Document

Publisher copy:: 10.1136/ard.62.1.90

Authors

+ Foxwell, B More by this author

Role:: Author

+ Andreakos, E More by this author

Role:: Author

+ Brennan, F More by this author

Role:: Author

+ Feldmann, M More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDORMS
Role:: Author

+ Smith, C More by this author

Role:: Author

More authors...

Journal:: Annals of the rheumatic diseases More from this journal
Volume:: 62 Suppl 2
Issue:: SUPPL. 2
Pages:: ii90-ii93
Publication date:: 2003-11-01
DOI:: 10.1136/ard.62.1.90
EISSN:: 1468-2060
ISSN:: 0003-4967

Language:: English
Keywords:: Arthritis, Rheumatoid

Tumor Necrosis Factor-alpha

Drug Design

Molecular Weight

Humans

Antirheumatic Agents
Pubs id:: pubs:224133
UUID:: uuid:f5f3e8d4-bc0e-486c-af18-1475545e85ed
Local pid:: pubs:224133
Source identifiers:: 224133
Deposit date:: 2012-12-19
ARK identifier:: ark:/29072/ora_f5f3e8d4bc0e486caf181475545e85ed

Terms of use

Copyright date:: 2003

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP